Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Aytu BioPharma, Inc. AYTU

Healthcare  —  Drug Manufacturers Specialty & Generic
2.28 (0.03) (1.30%) as of 25 Sep
Market cap
$25.1M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Aytu BioPharma Inc. (AYTU) Business Profile

Updated before January 2025

Company Overview

Aytu BioPharma Inc. (AYTU) is a specialty pharmaceutical company dedicated to developing and commercializing innovative products that address significant medical needs. Founded in 2015 and headquartered in Englewood, Colorado, AYTU has grown through strategic acquisitions and organic development to establish itself as a key player in the pharmaceutical and healthcare sectors. The company is led by a seasoned management team, including CEO Josh Disbrow, who brings extensive experience in the pharmaceutical and biotechnology industries. Under his leadership, AYTU has expanded its portfolio and market presence, focusing on both prescription and consumer health products.

Core Business Segments

AYTU operates across two primary business segments: Prescription Pharmaceuticals and Consumer Health Products.

Prescription Pharmaceuticals

AYTU’s prescription pharmaceutical segment focuses on addressing unmet medical needs in pediatrics, primary care, and specialty care. Key products in this category include:

  • Adzenys XR-ODT: A once-daily extended-release orally disintegrating tablet for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
  • Cotempla XR-ODT: Another ADHD treatment designed for children and adolescents, offering a unique delivery mechanism.
  • Karbinal ER: An extended-release antihistamine for the treatment of allergic conditions.
  • Poly-Vi-Flor and Tri-Vi-Flor: Prescription fluoride supplements designed to prevent dental cavities in children.

Consumer Health Products

AYTU’s consumer health division offers a range of over-the-counter (OTC) products aimed at improving overall health and wellness. These products include:

  • Diabasens: A topical cream designed to relieve nerve pain associated with diabetes.
  • FlutiCare: An OTC nasal spray for allergy relief.
  • Regoxidine: A hair regrowth treatment for men and women.
  • Vesele: A dietary supplement aimed at improving sexual health and vascular function.

This dual-segment approach allows AYTU to diversify its revenue streams and cater to a broad range of consumer and patient needs.

Business Model

AYTU’s business model is centered on the acquisition, development, and commercialization of differentiated pharmaceutical and consumer health products. The company generates revenue through:

  1. Product Sales: Direct sales of prescription and OTC products to healthcare providers, pharmacies, and consumers.
  2. Licensing Agreements: Collaborations with other pharmaceutical companies to expand the reach of its products.
  3. Strategic Partnerships: Partnerships with distributors and retailers to ensure widespread availability of its consumer health products.

AYTU’s vertically integrated approach enables it to manage the entire lifecycle of its products, from development and manufacturing to marketing and distribution.

Strategic Direction

AYTU is focused on expanding its product portfolio and market presence through:

  • Pipeline Development: Investing in research and development to bring new products to market, particularly in pediatrics and specialty care.
  • Geographic Expansion: Exploring opportunities to enter new markets, both domestically and internationally.
  • Sustainability Goals: Implementing environmentally friendly practices in its operations and supply chain.
  • Digital Transformation: Leveraging technology to enhance customer engagement and streamline operations.

The company is also exploring potential acquisitions to further diversify its portfolio and strengthen its competitive position.

Competitive Landscape

AYTU operates in a highly competitive environment, facing competition from both large pharmaceutical companies and smaller specialty firms. Key competitors include:

  • Teva Pharmaceuticals: A global leader in generic and specialty medicines.
  • Perrigo Company: Known for its extensive range of OTC products.
  • Hikma Pharmaceuticals: A major player in the generic and branded pharmaceutical markets.
  • Bausch Health: Competes in both prescription and consumer health segments.

Despite the competition, AYTU differentiates itself through its focus on niche markets and innovative product offerings.

Risk Factors

Like any pharmaceutical company, AYTU faces several risks, including:

  • Regulatory Challenges: Compliance with stringent FDA regulations and other international standards.
  • Market Dependence: Heavy reliance on a few key products for revenue generation.
  • Supply Chain Disruptions: Potential delays in manufacturing and distribution due to global supply chain issues.
  • Competitive Pressure: Intense competition from both established players and new entrants.
  • Economic Conditions: Fluctuations in consumer spending and healthcare budgets can impact sales.

Recent Developments

AYTU has recently made significant strides in expanding its product portfolio and market reach. Notable developments include:

  • Launch of New Products: Introduction of innovative treatments in the ADHD and allergy segments.
  • Strategic Acquisitions: Acquisition of complementary businesses to enhance its product offerings.
  • COVID-19 Impact: Adaptation to the challenges posed by the pandemic, including supply chain disruptions and shifts in consumer behavior.

These initiatives underscore AYTU’s commitment to growth and innovation.

Investment Considerations

Strengths

  • Diverse Portfolio: A balanced mix of prescription and OTC products.
  • Experienced Leadership: A management team with a proven track record.
  • Growth Potential: Opportunities for expansion in both existing and new markets.

Risks

  • Regulatory Hurdles: Potential delays in product approvals.
  • Market Volatility: Dependence on a few key products for revenue.
  • Competitive Landscape: Intense competition from larger players.

Investors should weigh these factors carefully when considering AYTU as a potential investment.

Conclusion

Aytu BioPharma Inc. is a dynamic and growing company with a strong focus on addressing unmet medical needs. Its diverse product portfolio, strategic initiatives, and commitment to innovation position it well for future growth. However, investors should remain mindful of the risks associated with the pharmaceutical industry. Overall, AYTU is well-positioned to capitalize on emerging opportunities and deliver long-term value to its stakeholders.